Delavan Comprehensive Treatment Center Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 1823 E Geneva St Ste 1807a, Delavan, WI 53115 Phone: 615-861-6000 |
News Archive
Somaxon Pharmaceuticals, Inc. today announced that it is offering to sell up to 4,000,000 shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as sole book-running manager in the offering. The co-manager in the offering is Oppenheimer & Co. Inc. Somaxon expects to grant the underwriters an option to purchase up to an additional 600,000 shares of common stock to cover overallotments of shares, if any.
A new analysis indicates that not obtaining a medication the first time it is prescribed-called initial medication non-adherence-is common among patients within the Catalan health system in Spain.
People who maintain that eating tomatoes can cause their gout to flare up are likely to welcome new research from New Zealand's University of Otago that has, for the first time, found a biological basis for this belief.
Exposure to a cancer-causing toxin that contaminates crops in developing countries can be reduced by a simple, cost-effective intervention on post-harvest storage, concludes a study in this week's issue of The Lancet.
America's biopharmaceutical research companies are intensifying research into rare diseases, which often are among the most devastating to patients and complex for researchers. A record 460 medicines for rare diseases are in late stages of the pipeline, either in clinical trials or awaiting Food and Drug Administration (FDA) review, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
› Verified 5 days ago